ReviewProstate cancer2013
Galectins as new prognostic markers and potential therapeutic targets for advanced prostate cancers.
Review in Prostate cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Article
- Galactose specific lectins from prostate tissue with different pathologies: biochemical and cellular studies.Molecular biology reports · 2022Article
- Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials.Biomolecules · 2020Review
- A Peptide Targeting Inflammatory CNS Lesions in the EAE Rat Model of Multiple Sclerosis.Inflammation · 2018Article
- Overexpression of the galectin-3 during tumor progression in prostate cancer and its clinical implications.International journal of clinical and experimental pathology · 2018Article
- Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers.Scientific reports · 2017Article
- Article
- Towards molecular mechanisms regulating the expression of galectins in cancer cells under microenvironmental stress conditions.Cellular and molecular life sciences : CMLS · 2015Review
- Microfluidic blood cell sorting: now and beyond.Small (Weinheim an der Bergstrasse, Germany) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A better understanding of multimolecular interactions involved in tumor dissemination is required to identify new effective therapies for advanced prostate cancer (PCa). Several groups investigated protein-glycan interactions as critical factors for crosstalk between prostate tumors and their microenvironment. This review both discusses whether the "galectin-signature" might serve as a reliable biomarker for the identification of patients with high risk of metastasis and assesses the galectin-glycan lattices as potential novel targets for anticancer therapies. The ultimate goal of this review is to convey how basic findings related to galectins could be in turn translated into clinical settings for patients with advanced PCa.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.